Cantor Fitzgerald Boosts Cypherpunk Technologies (NASDAQ:CYPH) Price Target to $4.90

Cypherpunk Technologies (NASDAQ:CYPH) had its price objective boosted by investment analysts at Cantor Fitzgerald from $1.60 to $4.90 in a research report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s price target points to a potential upside of 100.00% from the stock’s previous close.

A number of other equities analysts have also issued reports on the company. Weiss Ratings raised Cypherpunk Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 17th. Wall Street Zen upgraded Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, July 4th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Cypherpunk Technologies has a consensus rating of “Hold” and an average price target of $4.90.

Cypherpunk Technologies Stock Performance

NASDAQ CYPH opened at $2.45 on Thursday. The company has a 50-day simple moving average of $1.05 and a 200-day simple moving average of $0.91. Cypherpunk Technologies has a one year low of $0.28 and a one year high of $3.70. The firm has a market capitalization of $264.01 million, a PE ratio of 4.38 and a beta of 0.33.

Cypherpunk Technologies (NASDAQ:CYPH) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.18 earnings per share for the quarter.

Insider Transactions at Cypherpunk Technologies

In other news, Director Thomas Dietz sold 20,000 shares of Cypherpunk Technologies stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $1.72, for a total transaction of $34,400.00. Following the transaction, the director directly owned 132,500 shares in the company, valued at approximately $227,900. This trade represents a 13.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.50% of the company’s stock.

Institutional Trading of Cypherpunk Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in CYPH. Millennium Management LLC bought a new stake in Cypherpunk Technologies during the fourth quarter worth approximately $37,000. LPL Financial LLC acquired a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at $44,000. Sequoia Financial Advisors LLC bought a new stake in shares of Cypherpunk Technologies during the 4th quarter worth $56,000. Finally, HighTower Advisors LLC bought a new stake in shares of Cypherpunk Technologies during the 4th quarter worth $59,000. 30.46% of the stock is currently owned by institutional investors.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.